Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Sumitomo Dainippon

This page shows the latest Sumitomo Dainippon news and features for those working in and with pharma, biotech and healthcare.

BMS links up with Exscientia for $1.2bn AI drug discovery deal

BMS links up with Exscientia for $1.2bn AI drug discovery deal

Aside from its collaboration with BMS, Exscientia has a number of additional collaborations in place with other pharma companies, including Bayer, Sanofi and Dainippon Sumitomo.

Latest news

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • A snapshot of… Exscientia A snapshot of… Exscientia

    We have so far discovered four preclinical drug candidates, and recently announced the first drug designed by AI in partnership with Sumitomo Dainippon Pharma to enter human trials.

  • The good, the bad and the ugly The good, the bad and the ugly

    2020.”. Central Nervous System. 2017 was a quiet year in CNS. The most prominent growing companies were Merck &Co (49.8%), Takeda (39.1%) and Sumitomo Dainippon Pharma (25%), with growth ... However, the imminent US patent expiry of Sumitomo

  • Deal Watch December 2016 Deal Watch December 2016

    790. Tolero Pharma (US). Dainippon Sumitomo (Japan). Acquisition with milestones. Portfolio, including alvocidib, a CDK9 inhibitor with phase II completed in AML. ... Tolero Pharmaceuticals. Dainippon Sumitomo. $780m. Upfront payment of $200m.

  • Deal Watch August 2016 Deal Watch August 2016

    If apomorphine is the only product, the acquisition of the company by Sunovion (the US subsidiary of Dainippon Sumitomo) for $645m, paying a hefty 123% share price premium, looks very expensive ... 645. Cynapsys (CA). Sunovion (US) (Dainippon Sumitomo).

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    Edison Pharmaceuticals/ Dainippon Sumitomo Pharma. Strategic alliance. Extends development/ commercialisation agreement to EPI 743 and EPI 589 for mitochondrial disease, includes stock purchase and 10 further NCEs.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Civitas appoints Mark Iwicki as CEO Civitas appoints Mark Iwicki as CEO

    Sunovion was created after the acquisition of Iwicki's former company Sepracor by Dainippon Sumitomo Pharmaceuticals.

  • Boston Biomedical appoints commercial head Boston Biomedical appoints commercial head

    Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...

Quick links